Charles Duncan
Stock Analyst at Cantor Fitzgerald
(4.36)
# 424
Out of 4,749 analysts
255
Total ratings
50%
Success rate
18.47%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $34.00 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $38.25 | - | 17 | Dec 17, 2024 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $121 | $106.46 | +13.66% | 21 | Dec 12, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $11.48 | - | 7 | Dec 10, 2024 | |
| MRNS Marinus Pharmaceuticals | Reiterates: Overweight | $4 | $0.54 | +637.33% | 9 | Nov 14, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $38.77 | +49.60% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $31.53 | +36.38% | 5 | Oct 25, 2024 | |
| CYTK Cytokinetics | Reiterates: Overweight | n/a | $49.46 | - | 7 | Oct 18, 2024 | |
| PRTA Prothena Corporation | Reiterates: Overweight | n/a | $14.23 | - | 15 | Sep 30, 2024 | |
| ITCI Intra-Cellular Therapies | Reiterates: Overweight | $130 | $127.08 | +2.30% | 21 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $151.82 | +2.09% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.91 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.31 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 | $124.37 | +12.57% | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $23.30 | +50.21% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $28 | $18.66 | +50.05% | 20 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $4.41 | +194.78% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.91 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.72 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.79 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.55 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $22.56 | +50.71% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $40.30 | +24.07% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $3.18 | +57.23% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.68 | +488.41% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.96 | +317.58% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $39.98 | +45.07% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $110 | $1.65 | +6,566.67% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $4.49 | +1,681.74% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.41 | +112.77% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $9.27 | +18.66% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $6.50 | +84.62% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $8.69 | +1,833.26% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.24 | +792.86% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $16.19 | +1,135.33% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $0.66 | +502.95% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $2.38 | +908.40% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $2.09 | +6,789.95% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $2.87 | +39.37% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $408 → $480 | $4.84 | +9,817.36% | 4 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $56.64 | -31.14% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $66.92 | -77.59% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $1.23 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.64 | +2,610.84% | 1 | Oct 9, 2017 |
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $34.00
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $38.25
Upside: -
Axsome Therapeutics
Dec 12, 2024
Reiterates: Overweight
Price Target: $121
Current: $106.46
Upside: +13.66%
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.48
Upside: -
Marinus Pharmaceuticals
Nov 14, 2024
Reiterates: Overweight
Price Target: $4
Current: $0.54
Upside: +637.33%
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $38.77
Upside: +49.60%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $31.53
Upside: +36.38%
Cytokinetics
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $49.46
Upside: -
Prothena Corporation
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.23
Upside: -
Intra-Cellular Therapies
Sep 20, 2024
Reiterates: Overweight
Price Target: $130
Current: $127.08
Upside: +2.30%
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $151.82
Upside: +2.09%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.91
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.31
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $140
Current: $124.37
Upside: +12.57%
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $23.30
Upside: +50.21%
Aug 7, 2024
Maintains: Overweight
Price Target: $37 → $28
Current: $18.66
Upside: +50.05%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.41
Upside: +194.78%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.91
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.72
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.79
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.55
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $22.56
Upside: +50.71%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $40.30
Upside: +24.07%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $3.18
Upside: +57.23%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.68
Upside: +488.41%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.96
Upside: +317.58%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $39.98
Upside: +45.07%
Aug 22, 2023
Reiterates: Overweight
Price Target: $110
Current: $1.65
Upside: +6,566.67%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $4.49
Upside: +1,681.74%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.41
Upside: +112.77%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $9.27
Upside: +18.66%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $6.50
Upside: +84.62%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $8.69
Upside: +1,833.26%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.24
Upside: +792.86%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $16.19
Upside: +1,135.33%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $0.66
Upside: +502.95%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $2.38
Upside: +908.40%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $2.09
Upside: +6,789.95%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $2.87
Upside: +39.37%
May 19, 2020
Reiterates: Overweight
Price Target: $408 → $480
Current: $4.84
Upside: +9,817.36%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $56.64
Upside: -31.14%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $66.92
Upside: -77.59%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $1.23
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $6.64
Upside: +2,610.84%